Defrijet 500mg Tablet

Transfusional Iron Overload: Initial dose for patients with estimated glomerular filtration rate (eGFR) greater than 60 mL/min/1.73 m 2 is 14 mg per kg (calculated to nearest whole tablet ) once daily. NTDT Syndromes: Initial dose for patients with eGFR greater than 60 mL/min/1.73 m 2 is 7 mg per kg (calculated to nearest whole tablet) once daily. See full prescribing information for information regarding monitoring, administration, and dose-reductions for organ impairment.

Directions from the U.S. FDA-approved label for Deferasirox — your doctor or pharmacist may advise differently.

Deferasirox is contraindicated in patients with: Estimated GFR less than 40 mL/min/1.73 m 2; Poor performance status; High-risk myelodysplastic syndromes (this patient population was not studied and is not expected to benefit from chelation therapy); Advanced malignancies; Platelet counts less than 50 x 10 9 /L; Known hypersensitivity to deferasirox or any component of deferasirox. Estimated GFR less than 40 mL/min/1.73 m 2. Patients with poor performance status. Patients with high-risk myelodysplastic syndrome (MDS). Patients with advanced malignancies.

Excerpt from the U.S. FDA-approved label for Deferasirox. Talk to a pharmacist or doctor before use.

Acute Kidney Injury: Measure serum creatinine in duplicate before starting therapy. Monitor renal function during deferasirox therapy and reduce dose or interrupt therapy for toxicity. Hepatic Toxicity: Monitor hepatic function. Reduce dose or interrupt therapy for toxicity. Fatal and Nonfatal Gastrointestinal (GI) Bleeding, Ulceration, and Irritation: Risk may be greater in patients who are taking deferasirox in combination with drugs that have known ulcerogenic or hemorrhagic potential.

Warnings and precautions excerpt from the U.S. FDA-approved label for Deferasirox — not a complete list. Talk to a pharmacist or doctor before use.

The following clinically significant adverse reactions are also discussed in other sections of the labeling: Acute Kidney Injury, Including Acute Renal Failure Requiring Dialysis, and Renal Tubular Toxicity Including Fanconi Syndrome Hepatic Toxicity and Failure GI Hemorrhage Bone Marrow Suppression Hypersensitivity Severe Skin Reactions Skin Rash Auditory and Ocular Abnormalities In patients with transfusional iron overload,…

Excerpt from the U.S. FDA-approved label for Deferasirox — not a complete list. Talk to a pharmacist or doctor about side effects.

5 brands · 3 makers in the NepalDoc catalog — see the full Deferasirox guide →

Store deferasirox tablets at 20°C to 25°C (68°F to 77°F); Protect from moisture.

Storage information from the U.S. FDA-approved label for Deferasirox.